Drug Pipeline

Drug development in key areas of unmet need hit milestones this week, with Biogen, AstraZeneca, and Jaguar Health announcing regulatory steps with the FDA.

Gilead will present new data on virologic suppression in adults 65 years and older at AIDS 2020: Virtual this week.

In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.

Five pharma markers are recalling the diabetes medication due to the presence of a carcinogenic ingredient.

Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.

Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.

Major depression drug recalled over wrong dosage.

Pfizer bucks the trend with as high as 98.5% price cuts.

Approval of Ubrelvy follows several new migraine drugs.

Here are the top drugs expected to be approved this year and their financial impact.

New HIV prevention drug not indicated for women.

From breast cancer to prostate cancer, the state of oncology care and how it will evolve.

What to expect for these high-dollar drugs.

The vaccines that could make a big impact on healthcare, from radical new flu vaccines to simplified meningococcal vaccine regimens.

The disease management and insurer initiatives changing the diabetes landscape.

The latest in RA therapies, and what you can expect from the pipeline.

Managed Healthcare Executive asked top experts their predictions for the top game-changing therapies. Here’s what they said.

The biggest drug categories and medications set for approval this year.

Major blockbuster drugs slated for launch in 2019 are expected to have a significant impact on treating certain cancers, diabetes, peanut allergies, and other conditions.

Vaccines are an important part of creating “herd immunity” to keep infectious diseases in check. Here are three vaccine developments that have far reaching implications for public health.

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society, offers a quick overview of current developments as well as a look forward.

Have two minutes? Listen to this quick podcast for critical takeaways from three of our top articles.